| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 1999;34:876-881.)
© 1999 American Heart Association, Inc.
Scientific Contributions |
Role of Endothelin-1 in Hypertension
From the MRC Multidisciplinary Research Group on Hypertension, Clinical Research Institute of Montréal (IRCM), Québec, Canada.
Correspondence to Ernesto L. Schiffrin, MD, PhD, Clinical Research Institute of Montréal, 110, Avenue des Pins Ouest, Montréal, Québec, Canada H2W 1R7. E-mail schiffe{at}ircm.qc.ca
Abstract—Endothelin-1 (ET-1) is overexpressed in the vascular wall in certain models of experimental hypertension: deoxycorticosterone acetate salt–treated rats, deoxycorticosterone acetate salt–treated spontaneously hypertensive rats (SHR), stroke-prone SHR, Dahl salt–sensitive rats, angiotensin II–infused rats, and 1-kidney 1 clip Goldblatt rats; it is not overexpressed in SHR, 2-kidney 1-clip hypertensive rats, or L-NAME–treated rats. In hypertensive rats without generalized vascular overexpression, however, expression of ET-1 was often enhanced in intramyocardial coronary arteries, suggesting a role of endothelin in myocardial ischemia in hypertension. In rats overexpressing ET-1, ETA/B and ETA-selective receptor antagonists lowered blood pressure and reduced vascular growth, particularly in small arteries, beyond what could be attributed to blood pressure lowering, suggesting a direct effect of ET-1 on growth. Hypertensive rats treated with endothelin antagonists are protected from stroke and renal injury. The ETA/B antagonist bosentan induced blood-pressure reductions in mildly hypertensive patients similar to those achieved with an angiotensin-converting enzyme inhibitor. Moderately to severely hypertensive patients presented with enhanced expression of prepro-ET-1 mRNA in the endothelium of subcutaneous resistance arteries, suggesting that these stages of hypertension may respond particularly well to endothelin antagonism. Hypertensive patients with coronary artery disease have increased arterial expression of ET-1, and increased plasma levels of immunoreactive endothelin have been described in black patients. ET-1 plays an important role in atherosclerosis, for which hypertension is an important risk factor. Thus, ET-1 may be involved in experimental and human hypertension. Endothelin antagonists may prove effective as disease-modifying agents if they are shown clinically, as they are experimentally, to offer target organ protection and reduce long-term complications of hypertension. This remains to be demonstrated in humans.
Key Words: endothelin • hypertension, human essential • coronary artery disease • vascular hypertrophy
This article has been cited by other articles:
 |
|
 |
|
  N. R. Tykocki, C. E. Gariepy, and S. W. Watts Endothelin ETB Receptors in Arteries and Veins: Multiple Actions in the Vein J. Pharmacol. Exp. Ther., June 1, 2009; 329(3): 875 - 881. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Belaidi, M. Joyeux-Faure, C. Ribuot, S. H. Launois, P. Levy, and D. Godin-Ribuot Major role for hypoxia inducible factor-1 and the endothelin system in promoting myocardial infarction and hypertension in an animal model of obstructive sleep apnea. J. Am. Coll. Cardiol., April 14, 2009; 53(15): 1309 - 1317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Peltonen, P. Taskinen, J. Napankangas, H. Leskinen, P. Ohtonen, Y. Soini, T. Juvonen, J. Satta, O. Vuolteenaho, and H. Ruskoaho Increase in tissue endothelin-1 and ETA receptor levels in human aortic valve stenosis Eur. Heart J., January 2, 2009; 30(2): 242 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Dhaun, J. Goddard, D. E. Kohan, D. M. Pollock, E. L. Schiffrin, and D. J. Webb Role of Endothelin-1 in Clinical Hypertension: 20 Years On Hypertension, September 1, 2008; 52(3): 452 - 459. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Xu, G. D. Fink, and J. J. Galligan Increased sympathetic venoconstriction and reactivity to norepinephrine in mesenteric veins in anesthetized DOCA-salt hypertensive rats Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H160 - H168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. O. Lillie, M. Mahata, S. Khandrika, F. Rao, R. A. Bundey, G. Wen, Y. Chen, L. Taupenot, D. W. Smith, S. K. Mahata, et al. Heredity of Endothelin Secretion: Human Twin Studies Reveal the Influence of Polymorphism at the Chromogranin A Locus, a Novel Determinant of Endothelial Function Circulation, May 1, 2007; 115(17): 2282 - 2291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Chansel, M. Ciroldi, S. Vandermeersch, L. F Jackson, A.-M. Gomez, D. Henrion, D. C. Lee, T. M. Coffman, S. Richard, J.-C. Dussaule, et al. Heparin binding EGF is necessary for vasospastic response to endothelin FASEB J, September 1, 2006; 20(11): 1936 - 1938. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Feletou and P. M. Vanhoutte Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture) Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H985 - H1002. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Bagnall, N. F. Kelland, F. Gulliver-Sloan, A. P. Davenport, G. A. Gray, M. Yanagisawa, D. J. Webb, and Y. V. Kotelevtsev Deletion of Endothelial Cell Endothelin B Receptors Does Not Affect Blood Pressure or Sensitivity to Salt Hypertension, August 1, 2006; 48(2): 286 - 293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Wang, A. F. Chen, and D. H. Wang ETA receptor blockade prevents renal dysfunction in salt-sensitive hypertension induced by sensory denervation Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H2005 - H2011. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Rodriguez-Vita, M. Ruiz-Ortega, M. Ruperez, V. Esteban, E. Sanchez-Lopez, J. J. Plaza, and J. Egido Endothelin-1, via ETA Receptor and Independently of Transforming Growth Factor-{beta}, Increases the Connective Tissue Growth Factor in Vascular Smooth Muscle Cells Circ. Res., July 22, 2005; 97(2): 125 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Dutil, V. Eliopoulos, E.-L. Marchand, A. M. Devlin, J. Tremblay, K. Prithiviraj, P. Hamet, A. Migneault, D. deBlois, and A. Y. Deng A quantitative trait locus for aortic smooth muscle cell number acting independently of blood pressure: implicating the angiotensin receptor AT1B gene as a candidate Physiol Genomics, May 11, 2005; 21(3): 362 - 369. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Wang and D. H. Wang Prevention of endothelin-1-induced increases in blood pressure: role of endogenous CGRP Am J Physiol Heart Circ Physiol, October 1, 2004; 287(4): H1868 - H1874. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Endemann and E. L. Schiffrin Endothelial Dysfunction J. Am. Soc. Nephrol., August 1, 2004; 15(8): 1983 - 1992. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Schiffrin and R. M. Touyz From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension Am J Physiol Heart Circ Physiol, August 1, 2004; 287(2): H435 - H446. [Full Text] [PDF]
|
|
|
|
|
|
C. Cardillo, U. Campia, M. Iantorno, and J. A. Panza Enhanced Vascular Activity of Endogenous Endothelin-1 in Obese Hypertensive Patients Hypertension, January 1, 2004; 43(1): 36 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Pu, M. F. Neves, A. Virdis, R. M. Touyz, and E. L. Schiffrin Endothelin Antagonism on Aldosterone-Induced Oxidative Stress and Vascular Remodeling Hypertension, July 1, 2003; 42(1): 49 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Quaschning, S. Kocak, C. Bauer, H.-H. Neumayer, J. Galle, and B. Hocher Increase in nitric oxide bioavailability improves endothelial function in endothelin-1 transgenic mice Nephrol. Dial. Transplant., March 1, 2003; 18(3): 479 - 483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Rothermund, R. Vetter, M. Dieterich, P. Kossmehl, O. Gogebakan, C. Yagil, Y. Yagil, and R. Kreutz Endothelin-A Receptor Blockade Prevents Left Ventricular Hypertrophy and Dysfunction in Salt-Sensitive Experimental Hypertension Circulation, October 29, 2002; 106(18): 2305 - 2308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Imig, M. D. Breyer, and R. M. Breyer Contribution of prostaglandin EP2 receptors to renal microvascular reactivity in mice Am J Physiol Renal Physiol, September 1, 2002; 283(3): F415 - F422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Grubbs, M. P. Anstadt, and A. Ergul Saphenous Vein Endothelin System Expression and Activity in African American Patients Arterioscler. Thromb. Vasc. Biol., July 1, 2002; 22(7): 1122 - 1127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. V. Balyakina, D. Chen, M. L. Lawrence, S. Manning, R. E. Parker, S. B. Shappell, and B. Meyrick ET-1 receptor gene expression and distribution in L1 and L2 cells from hypertensive sheep pulmonary artery Am J Physiol Lung Cell Mol Physiol, July 1, 2002; 283(1): L42 - L51. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ko, A. Maitland, P. W.M. Fedak, A. S. Dumont, M. Badiwala, F. Lovren, C. R. Triggle, T. J. Anderson, V. Rao, and S. Verma Endothelin blockade potentiates endothelial protective effects of ace inhibitors in saphenous veins Ann. Thorac. Surg., April 1, 2002; 73(4): 1185 - 1188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. A. Abassi, S. Ellahham, J. Winaver, and A. Hoffman The Intrarenal Endothelin System and Hypertension Physiology, August 1, 2001; 16(4): 152 - 156. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Ballew and G. D. Fink Role of ETA receptors in experimental ANG II-induced hypertension in rats Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2001; 281(1): R150 - R154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Ruschitzka, T. Quaschning, G. Noll, A. deGottardi, M. F. Rossier, F. Enseleit, D. Hurlimann, T. F. Luscher, and S. G. Shaw Endothelin 1 Type A Receptor Antagonism Prevents Vascular Dysfunction and Hypertension Induced by 11{beta}-Hydroxysteroid Dehydrogenase Inhibition : Role of Nitric Oxide Circulation, June 26, 2001; 103(25): 3129 - 3135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Ballew, S. W. Watts, and G. D. Fink Effects of Salt Intake and Angiotensin II on Vascular Reactivity to Endothelin-1 J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 345 - 350. [Abstract] [Full Text]
|
|
|
|
|
|
E. M. A. Mervaala, Z. J. Cheng, I. Tikkanen, R. Lapatto, K. Nurminen, H. Vapaatalo, D. N. Muller, A. Fiebeler, U. Ganten, D. Ganten, et al. Endothelial Dysfunction and Xanthine Oxidoreductase Activity in Rats With Human Renin and Angiotensinogen Genes Hypertension, February 1, 2001; 37(2): 414 - 418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Elijovich, C. L. Laffer, E. Amador, H. Gavras, M. R. Bresnahan, and E. L. Schiffrin Regulation of Plasma Endothelin by Salt in Salt-Sensitive Hypertension Circulation, January 16, 2001; 103(2): 263 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. DUSSAULE, P.-L. THARAUX, J.-J. BOFFA, F. FAKHOURI, R. ARDAILLOU, and C. CHATZIANTONIOU Mechanisms Mediating the Renal Profibrotic Actions of Vasoactive Peptides in Transgenic Mice J. Am. Soc. Nephrol., November 1, 2000; 11(90002): S124 - S128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Fernandez-Patron, K. G. Stewart, Y. Zhang, E. Koivunen, M. W. Radomski, and S. T. Davidge Vascular Matrix Metalloproteinase-2-Dependent Cleavage of Calcitonin Gene-Related Peptide Promotes Vasoconstriction Circ. Res., October 13, 2000; 87(8): 670 - 676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. N. Muller, E. M. A. Mervaala, F. Schmidt, J.-K. Park, R. Dechend, E. Genersch, V. Breu, B.-M. Loffler, D. Ganten, W. Schneider, et al. Effect of Bosentan on NF-{kappa}B, Inflammation, and Tissue Factor in Angiotensin II-Induced End-Organ Damage Hypertension, August 1, 2000; 36(2): 282 - 290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ergul Hypertension in Black Patients : An Emerging Role of the Endothelin System in Salt-Sensitive Hypertension Hypertension, July 1, 2000; 36(1): 62 - 67. [Abstract] [Full Text] [PDF]
|
|